Bristol-Myers Squibb Prices $2.0 Billion of Senior Notes

Bristol-Myers Squibb Prices $2.0 Billion of Senior Notes

<0> Bristol-Myers Squibb CompanyJennifer Fron Mauer, 609-252-6579orTimothy Power, 609-252-7509 </0>

(NYSE:BMY) announced today that it has agreed to sell $2.0 billion of senior unsecured notes: $750 million in aggregate principal amount of 0.875% notes due 2017, $750 million in aggregate principal amount of 2.000% notes due 2022 and $500 million in aggregate principal amount of 3.250% notes due 2042 in an underwritten public offering.

Citigroup Global Markets Inc., Barclays Capital Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Merrill Lynch Pierce Fenner & Smith Incorporated and Wells Fargo Securities, LLC are acting as joint book-running managers of the underwriters.

Bristol-Myers Squibb intends to use the net proceeds from the offering, the issuance of commercial paper and cash on hand to finance the acquisition of Amylin Pharmaceuticals, Inc., pay costs and expenses pursuant to the assumption agreements, to pay fee and expenses and/or for general corporate purposes. The offering is expected to close on July 31, 2012, subject to customary closing conditions.

When available, the final prospectus supplement and accompanying prospectus relating to the offering of the notes may be obtained by contacting one of the following joint book-running managers:

The final prospectus supplement and accompanying prospectus, when available, may also be accessed through the SEC's website at .

These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.